The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors

This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalati

Trial Details

NCT ID

NCT07459283

Phase

EARLY_PHASE1

Sponsor

FindCure Biosciences (ZhongShan) Co., Ltd.

Status

RECRUITING

Cancer Type

Thyroid Cancer

Interventions

• INN805

Locations (sample)

• Wuxi, Jiangsu, China|31.56887,120.28857

Key Eligibility Criteria

• Aged 18 to 75 years old male and female.
• Patients with advanced malignant solid tumors who have failed standard treatments.
• According to RECIST 1.1, there is at least one measurable lesion.
• ECOG performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Thyroid Cancer Trials on Trialify →